Postgraduate Course: Commercial Aspects of Drug Discovery (PGBI11076)

Course Outline
School	School of Biological Sciences	College	College of Science and Engineering
Credit level (Normal year taken)	SCQF Level 11 (Postgraduate)	Availability	Not available to visiting students
SCQF Credits	10	ECTS Credits	5
Summary	Online Distance Learning Course This course gives the student a general, illustrated overview over the different stages in drug discovery from the industrial perspective. A wide range of biotech and pharma business models will be presented and analysed including non-profit models for drug discovery through government agencies. The practicalities of starting up a new company in the biotech area will be explored and ideas and business plans for potential start up companies will be evaluated.
Course description	Not entered

Entry Requirements (not applicable to Visiting Students)
Pre-requisites		Co-requisites
Prohibited Combinations		Other requirements	None

Course Delivery Information

Academic year 2017/18, Not available to visiting students (SS1)		Quota: None
Course Start	Semester 2
Course Start Date	15/01/2018
Timetable	Timetable
Learning and Teaching activities (Further Info)	Total Hours: 100 ( Online Activities 20, Programme Level Learning and Teaching Hours 2, Directed Learning and Independent Learning Hours 78 )
Assessment (Further Info)	Written Exam 0 %, Coursework 100 %, Practical Exam 0 %
Additional Information (Assessment)	50 % group assessment (including maximum 20% variation for Peer Assessment of contribution) 50 % electronic portfolio comprising learning log and contribution to Skills Profile
Feedback	Not entered
No Exam Information

Learning Outcomes
On completion of this course, the student will be able to: At the end of this course a student should have: Knowledge of the cost structure of a traditional pharmaceutical corporation. An understanding of the development pipeline of a major pharmaceutical corporation Knowledge of the regulatory hurdles that must be passed to bring a new compound to market and the costs associated with these hurdles An ability to put together and evaluate a business plan for a start-up biotech company.